Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE